GRANTS & Funding 

TRI Foundation 2022 research grants

In 2022, the TRI Foundation is pleased to offer two grant schemes in breast cancer and kidney disease research. Both grant schemes are for early to mid-career TRI-based researchers and affiliated clinicians.  Applications are now open for both until 5th September 2022. READ MORE 

Linc Grant Scheme 2022 

TRI, Metro South Health, Mater and Children's Health Queensland (Oncology Department) have joined together to offer the annual LINC grants, worth up to $50,000 each. These grants are aimed at fostering new collaborative research projects between TRI-based researchers and Mater, Metro South Health, Mater or Children's Health Queensland clinicians. FIND OUT MORE 

TRI-CSIRO Grant Scheme 2022 

TRI and the CSIRO Australian e-Health Research Centre are offering three $100,000 grants for collaborative research projects aimed at solving a healthcare challenge. All grant applications must involve a TRI-based researcher, CSIRO Australian e-Health Research Centre scientist and a TRI partner clinician (from either Metro South Health, Mater or Children's Health Queensland). Applications for the grants will open on Monday 8th August 2022. FIND OUT MORE

Requesting a Letter of support from TRI for Funding 

If you are interested in applying for funding support from TRI please contact [email protected] for a link to the application form.  Applications need to be made three weeks prior to the submission deadline for the relevant grant applications, and must include:

  1. What is novel about the proposal and what is its value-add as a TRI investment for the TRI community.
  2. Previous funding requests to TRI (successful or not) to the same or a different funding body.
  3. How the application meets each of the criteria against which it will be assessed by TRI.
  4. Support from the Institute Director at TRI of the primary applicant (CIA).

    Read the full eligibility criteria and terms and conditions here

    past FUNDING PROGRAMS AT TRI

    Between 2015 and 2019. TRI ran the Spore and Drive grant schemes for translational research projects based at the institute. The aim was to support researchers progress their discoveries and translate their findings into the clinic. During the time the schemes run, TRI awarded $850,000 via 13 grants, with TRI’s partner institutions and industry collaborators matched this funding with a further $1,571,745. 

    Year awarded

    Grant scheme

    Principal Investigator

    Project title

    2015

    Spore

    Dr Michelle Hill

    Obesity-induced Barrett’s oesophagus and associated cancer: mechanisms and diagnostic tools

    2015

    Spore

    Dr Antje Blumenthal

    Towards biomarkers for patient stratification in sepsis

    2015

    Spore

    Prof Rik Thompson

    Portable, single-sided MRI for routine, low-cost analysis of mammographic density

    2015

    Spore

    Prof Ken O'Byrne

    Nucleoplasmin (NPM)1 a critical repair protein required for genomic stability

    2016

    Spore

    A/Prof Jyotsna Batra

    Novel MicroRNA’s as potential targets for treating prostate cancer

    2016

    Spore

    A/Prof Chamindie Punyadeera

    Circulating Tumour Cells as Biomarkers to Identify Head and Neck Cancer Patients for PD1 Therapy

    2018

    Spore

    Prof Gerald Holtmann

    Modulation of the GI Microbiome with probiotics to treat constipation

    2018

    Spore

    Prof John Hooper

    Theranostic biomolecules for improved diagnosis and treatment of pancreatic cancer

    2018

    Spore

    Dr Arutha Kulasinghe

    Can liquid biopsy provide predictive biomarkers for checkpoint inhibitor response in Non-Small Cell Lung Cancer?

    2018

    Spore

    Prof Peter Soyer

    Towards clinical diagnosis of inflammatory skin rashes using minimally‐invasive micro-sampling technologies

    2019

    Spore

    A/Prof Jyotsna Batra

    Improving the PSA test to detect all lethal prostate cancers

    2019

    Spore

    Prof Ben Panizza

    Therapeutic Potential for the Treatment of Adenoid Cystic Carcinoma (ACC)

    2019

    Drive

    Prof Sandro Porceddu

    Durvax Trial: A Phase 1b, single centre, open label study of a therapeutic Human Papilomavirus (HPC) DNA vaccine co-administered with anti-PD-L1 immunotheraphy, Duravalumab (MED14736), for recurrent and/or metastatic HPV-related oropharnygeal cancer

    2021

    LINC

    Dr Justine Gibson
    Dr Giorgia Mori

    Dysbiosis as a long-term sequelae in patients that undergo treatment for tuberculosis

    2021

    LINC

    Dr Sidharth Mantha
    Dr Thomas Kryza

    Establishing a pipeline for rapid clinical translation of novel biomaterials for the treatment of brain cancer of metastatic origin

    2021

    LINC

    A/Prof Erin McMeniman
    Dr Snehlata Kumari

    Determining Causative Mechanisms of Hidradenitis Suppurativa

    2021

    LINC

    Dr Philip Rowell
    Dr Lisa Philp

    Elucidating the Role of Adipokine Axis Dysregulation in Bone Metastatic Cancer for the Strategic Positioning of New Therapeutic Agents

    2021

    LINC

    Dr Timothy Edwards
    Dr Yuanhao Yang

    Making treatment-resistant schizophrenia more treatable: predicting life-threatening clozapine-induced-neutropenia using cellular genomics.

    2021

    LINC

    Dr Yoon-Kyo An
    Dr Kavita Bisht

    Identifying mechanism and new therapies to treat anaemia of inflammation in Inflammatory Bowel Diseases

    2021

    LINC

    Dr Reuben Beer
    Dr Marcus Gray

    Linking Advanced Neuroimaging, Disease State and Clinical Measures in Multiple Sclerosis: A multi-disciplinary and multi-institutional research approach.

    2021

    LINC

    Dr Jesrine Hong
    Dr Sandra Richardson

    DNA methylation in circulating free fetal DNA: A potential biomarker to predict fetal growth restriction and severe perinatal outcomes?